Vascular risk factor detection and control may prevent Alzheimer's disease

Jack C de la Torre1

  • 1Center for Alzheimer's Research, Banner Sun Health Research Institute, Sun City, AZ 85351, USA. jcdelatorre@comcast.net

Insights

Vascular risk factors significantly contribute to cognitive decline and Alzheimer disease (AD). Early detection using non-invasive vascular screening may enable timely interventions to prevent or delay dementia onset.

Area of Science:

  • Neurology
  • Cardiology
  • Gerontology

Background:

  • The vascular hypothesis of Alzheimer disease (AD) posits that vascular risk factors (VRF) are critical in cognitive decline.
  • Cardiovascular and carotid artery disease can lead to chronic brain hypoperfusion (CBH) decades before cognitive symptoms manifest.

Purpose of the Study:

  • To propose a preliminary randomized clinical study for early detection of VRF in cognitively healthy individuals.
  • To investigate the potential of non-invasive vascular screening to identify individuals at risk for cognitive decline due to CBH.

Main Methods:

  • Screening of middle-aged individuals using carotid Doppler ultrasound, echocardiography, and ankle-brachial index.
  • Utilizing non-invasive, cost-effective, and accurate office-based tools for VRF detection.
  • Employing secondary screening tools like neuroimaging, neurocognitive testing, and CSF markers for confirmation.

Main Results:

  • Non-invasive vascular screening can identify asymptomatic individuals at high risk for progressive cognitive decline.
  • Early detection of VRF in the heart or carotid arteries allows for timely medical intervention.
  • Targeted treatment based on VRF detection may prevent or slow cognitive deterioration.

Conclusions:

  • Prevention-by-detection of VRF through non-invasive vascular screening offers a promising strategy for dementia prevention.
  • This approach could promote healthier cognitive aging and reduce the societal burden of dementia.
  • Optimizing management of cardiovascular and carotid artery disease is crucial for brain health.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...